Artisan Partners Limited Partnership Acquires 253,363 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Artisan Partners Limited Partnership increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 3.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,712,874 shares of the biopharmaceutical company’s stock after purchasing an additional 253,363 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.06% of Halozyme Therapeutics worth $294,632,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Halozyme Therapeutics by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 13,335,155 shares of the biopharmaceutical company’s stock valued at $527,273,000 after buying an additional 38,342 shares in the last quarter. Snyder Capital Management L P increased its holdings in shares of Halozyme Therapeutics by 0.7% in the 2nd quarter. Snyder Capital Management L P now owns 4,323,512 shares of the biopharmaceutical company’s stock worth $155,949,000 after purchasing an additional 28,328 shares in the last quarter. Macquarie Group Ltd. raised its stake in shares of Halozyme Therapeutics by 22.8% in the first quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock worth $122,226,000 after purchasing an additional 595,220 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Halozyme Therapeutics by 3.8% in the second quarter. Geode Capital Management LLC now owns 2,730,268 shares of the biopharmaceutical company’s stock worth $98,481,000 after purchasing an additional 98,881 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Halozyme Therapeutics by 161.2% in the second quarter. Marshall Wace LLP now owns 2,323,523 shares of the biopharmaceutical company’s stock worth $83,809,000 after purchasing an additional 1,433,856 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. HC Wainwright decreased their price target on Halozyme Therapeutics from $61.00 to $48.00 and set a “buy” rating for the company in a research note on Thursday, January 18th. JMP Securities reiterated a “market outperform” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, January 18th. StockNews.com cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Benchmark reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, January 19th. Finally, The Goldman Sachs Group reduced their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, January 18th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.45.

Read Our Latest Stock Analysis on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded down $0.07 during mid-day trading on Thursday, hitting $35.24. 799,498 shares of the company traded hands, compared to its average volume of 1,677,226. The stock’s fifty day moving average price is $36.63 and its 200-day moving average price is $38.51. Halozyme Therapeutics, Inc. has a one year low of $29.85 and a one year high of $51.45. The company has a quick ratio of 6.51, a current ratio of 7.63 and a debt-to-equity ratio of 6.01. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of 18.78, a price-to-earnings-growth ratio of 0.36 and a beta of 1.22.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.02. Halozyme Therapeutics had a return on equity of 190.74% and a net margin of 32.52%. The business had revenue of $216.03 million during the quarter, compared to analyst estimates of $219.47 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 2.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.63, for a total value of $396,300.00. Following the completion of the transaction, the senior vice president now owns 151,911 shares of the company’s stock, valued at $6,020,232.93. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.